Gut microbiota in phytopharmacology: A comprehensive overview of concepts, reciprocal interactions, biotransformations and mode of actions

Pharmacol Res. 2019 Sep:147:104367. doi: 10.1016/j.phrs.2019.104367. Epub 2019 Jul 22.

Abstract

The dynamic and delicate interactions amongst intestinal microbiota, metabolome and metabolism dictates human health and disease. In recent years, our understanding of gut microbial regulation of intestinal immunometabolic and redox homeostasis have evolved mainly out of in vivo studies associated with high-fat feeding induced metabolic diseases. Techniques utilizing fecal transplantation and germ-free mice have been instrumental in reproducibly demonstrating how the gut microbiota affects disease pathogenesis. However, the pillars of modern drug discovery i.e. evidence-based pharmacological studies critically lack focus on intestinal microflora. This is primarily due to targeted in vitro molecular-approaches at cellular-level that largely overlook the etiology of disease pathogenesis from the physiological perspective. Thus, this review aims to provide a comprehensive understanding of the key notions of intestinal microbiota and dysbiosis, and highlight the microbiota-phytochemical bidirectional interactions that affects bioavailability and bioactivity of parent phytochemicals and their metabolites. Potentially by focusing on the three major aspects of gut microbiota i.e. microbial abundance, diversity, and functions, I will discuss phytochemical-microbiota reciprocal interactions, biotransformation of phytochemicals and plant-derived drugs, and pre-clinical and clinical efficacies of herbal medicine on dysbiosis. Additionally, in relation to phytochemical pharmacology, I will briefly discuss the role of dietary-patterns associated with changes in microbial profiles and review pharmacological study models considering possible microbial effects. This review therefore, emphasize on the timely and critically needed evidence-based phytochemical studies focusing on gut microbiota and will provide newer insights for future pre-clinical and clinical phytopharmacological interventions.

Keywords: 3,4-Dihydroxybenzoic (PubChem CID: 72); 8-Prenylnaringenin (PubChem CID: 480764); Alloxan (PubChem CID: 5781); Amygdalin (PubChem CID: 656516); Anthocyanins (PubChem CID: 145858); Anthracene (PubChem CID: 8418); Baicalein (PubChem CID: 5281605); Baicalin (PubChem CID: 64982); Berberine (PubChem CID: 2353); Biotransformation; Butyrate (PubChem CID: 104775); Camptothecin (PubChem CID: 24360); Carbon tetrachloride (PubChem CID: 5943); Carrageenan (PubChem CID: 6850766); Catechin (PubChem CID: 9064); Chebulinic acid (PubChem CID: 72284); Compound K (PubChem CID: 5481990); Curcumin (PubChem CID: 969516); Cyanide (PubChem CID: 5975); Cyanidin-3-glucoside (PubChem CID: 197081); Daidzin (PubChem CID: 107971); Diethylnitrosamine (PubChem CID: 5921); Digoxin (PubChem CID: 2724385); Dihydroberberine (PubChem CID: 10217); Dihydrodaidzein (PubChem CID: 176907); Dihydrodegoxin (PubChem CID: 92217); Ellagic acid (PubChem CID: 5281855); Equol (PubChem CID: 91469); Flavan-3-ol (PubChem CID: 3707243); Flavanone (PubChem CID: 10251); Flavonols (PubChem CID: 11349); Gallic acid (PubChem CID: 370); Ginsenoside Rb1 (PubChem CID: 135398523); Hydroxybenzoic acid (PubChem CID: 7420); Hydroxyhippuric acid (PubChem CID: 450268); Hydroxyphenyl propionc acid (PubChem CID: 10394); Irinotecan (PubChem CID: 60838); Irisolidone (PubChem CID: 5281781); Isoflavone (PubChem CID: 72304); Isorhamnetin (PubChem CID: 5281654); Isoxanthohumol (PubChem CID: 513197); Kakkalide (PubChem CID: 5490351); Lipopolysaccharide (PubChem CID: 11970143); Microbiota; Naringin (PubChem CID: 442428); Nutrition; Obesity; Oleandrin (PubChem CID: 11541511); Pectin (PubChem CID: 441476); Pharmacology; Phenylacetic acid (PubChem CID: 999); Phytochemicals; Pyrogallol (PubChem CID: 1057); Quercetin (PubChem CID: 5280343); Rheinanthrone (PubChem CID: 119396); Rutin (PubChem CID: 5280805); Scopolamine (PubChem CID: 3000322); Sennoside A (PubChem CID: 73111); Streptozotocin (PubChem CID: 29327); Tectoridin (PubChem CID: 5281810); Tectorigenin (PubChem CID: 5281811); Tetrahydrocurcumin (PubChem CID: 124072); Tetrahydrodaidzein (PubChem CID: 53628980); Urolithin A (PubChem CID: 5488186); Vitexin (PubChem CID: 5280441); γ-Valerolactones (PubChem CID: 7921).

Publication types

  • Review

MeSH terms

  • Animals
  • Biotransformation
  • Diet
  • Gastrointestinal Microbiome / drug effects*
  • Humans
  • Phytochemicals / pharmacokinetics
  • Phytochemicals / pharmacology*
  • Phytotherapy*

Substances

  • Phytochemicals